XML 87 R26.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Commitments and Contingencies | 9 Months Ended
--- | ---
Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract] |
Commitments and Contingencies Disclosure | Commitments and Contingencies In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired Fumapharm Products. We are required to make additional contingent payments to former shareholders of Fumapharm AG based on the attainment of certain cumulative sales levels of Fumapharm Products, with the amount of each payment based on the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement:
|  | Cumulative Sales Level
Prior 12 Month Sales |  | $1.0B |  | $2.0B |  | $3.0B |  | Each additional $1.0B up to $20.0B
|  | Payment Amounts (In Millions)
< $500 million |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
$500 million - $1.0 billion |  | 25.0 |  |  | 50.0 |  |  | 50.0 |  |  | 50.0 |
$1.0 billion - $1.5 billion |  | 50.0 |  |  | 100.0 |  |  | 100.0 |  |  | 100.0 |
$1.5 billion - $2.0 billion |  | — |  |  | 150.0 |  |  | 150.0 |  |  | 150.0 |
$2.0 billion - $2.5 billion |  | — |  |  | 200.0 |  |  | 200.0 |  |  | 200.0 |
$2.5 billion - $3.0 billion |  | — |  |  | — |  |  | 250.0 |  |  | 250.0 |
> $3.0 billion |  | — |  |  | — |  |  | — |  |  | 300.0 |
These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60 days following the end of the quarter in which the applicable cumulative sales level has been reached. During the nine months ended September 30, 2014, we paid a $25.0 million contingent payment as we reached the $1.0 billion cumulative sales level related to the Fumapharm Products in 2013, a $150.0 million contingent payment as we reached the $2.0 billion cumulative sales level related to Fumapharm Products in the second quarter of 2014 and accrued $200.0 million upon reaching $3.0 billion in total cumulative sales of Fumapharm Products, in the third quarter of 2014.

X
- Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308 + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration